Podcast Summary: Dr. Chapa’s OBGYN Clinical Pearls

Episode: Vaginal GSpot Injection: Again?
Date: March 29, 2026
Host: Dr. Chapma

Episode Overview

This episode delves into the topic of the G-spot injection (aka "G-shot") and its resurfacing in popular and clinical conversations, particularly in light of a new randomized controlled trial (RCT) investigating platelet-rich plasma (PRP) injections into the anterior vaginal wall for sexual function. Dr. Chapma critically evaluates the evidence, provides historical context, and discusses the anatomical, clinical, and ethical considerations surrounding this emerging—and controversial—practice.

Key Discussion Points & Insights

1. Background of the G-Spot and the G-Shot (01:09–03:59)

• G-Spot vs. G-Shot:
  • The G-spot is a controversial erogenous zone in the anterior vaginal wall.
  • The "G-shot" is an injection (historically collagen, now also PRP) aimed at enhancing this area to improve sexual function.
  • Plastic surgeons popularized the procedure via media (notably, Dr. 90210).
• Clinical Skepticism:
  • Many providers, including the speakers, express doubt about the scientific validity and significant placebo effects.
  • "A lot of the women that I've injected, some women come in and say, oh, my God, it's the best thing that’s ever happened. I have some women that come and be like, didn’t feel much of a difference. I don’t know." (Casual Commentator, 01:28)

2. Rise of PRP Injections & New Study (03:59–11:18)

• Historical Trajectory:
  • PRP was originally used in hematology for thrombocytopenia, later adopted in dental/maxillofacial and orthopedic fields for tissue regeneration and healing.
• Use in Gynecology:
  • Off-label PRP injections have been tried for vaginal rejuvenation, lichen sclerosus, and even premature ovarian insufficiency, though it remains experimental.
• Current Evidence:
  • PRP for G-spot/vaginal injection is not FDA-approved for any gynecological indication.
  • New RCT (Green Journal, Mar 19, 2026):
    • Title: Vaginal Injection of Platelet Rich Plasma for Sexual Function
    • Authors include leading figures in urogynecology (e.g., Barbie Garcia, Cheryl Iglesia).

"The problem is, you got to keep getting some injections because nobody knows if you just need one, if you need four, if you need five. ... Right now, you just can't order from a company your little vials of PRP. ... These are mainly all done off-label." (Dr. Chapma, 05:00–06:12)

3. Anatomical Rationale & Mechanistic Theory (09:48–11:18)

• Why the Anterior Vaginal Wall?
  • Homologous to sensitive male anatomy; strong sensory innervation.
  • Proximity to clitoral "wishbone" structure and trigone/bladder neck area.
  • Anatomically plausible as an erogenous zone but not universally so.

"The anterior vaginal wall absolutely is considered an erogenous zone. So the idea of anything that can plump that area up ... bring natural healing ... that’s the idea." (Dr. Chapma, 10:40)

4. RCT Review: Design, Results & Critical Appraisal (12:50–20:22)

• Study Design:
  • Small, pilot RCT (Single center, single-blind, N=52; 26 PRP, 26 control).
  • Included women age 18–50 without severe sexual dysfunction (already baseline functional).
  • Used the validated Female Sexual Function Index (FSFI) to assess outcomes.
• Intervention:
  • PRP or control injected into the anterior vaginal wall (approx. 3 cm from urethral meatus).
  • Follow-up at 6 weeks (primary) and 6 months (secondary).
• Findings:
  • Both at 6 weeks and 6 months, the PRP group had a numerically greater increase in FSFI scores (desire, arousal, lubrication, orgasm) than control.
  • BUT: No statistically significant difference.
  • Subjective patient global impression of improvement score favored PRP, but again, clinical significance is questionable given small sample and lack of baseline dysfunction.
• Adverse Events:
  • No serious events; theoretical risks of urinary hesitancy or obstruction if injection technique is flawed.
• Critical Perspective:
  • Study not powered for commercial application; procedure remains investigational.
  • Further, larger multicenter trials needed.

"Results are like, okay. I mean, they're not like, wow, this is amazing ... It opens up the discussion." (Dr. Chapma, 13:58)

"Even though ... changes were not statistically significantly different compared to control." (Dr. Chapma, quoting the paper, 15:50)

5. Context, Skepticism & Take-Home (18:00–20:22)

• Cyclical Trend:
  • Adds historical perspective: Dr. 90210’s collagen G-shot over a decade ago was also met with professional skepticism.
  • Medical groups and professional societies remain hesitant due to lack of robust evidence and potential risks.
• Ethics & Pragmatism:
  • Off-label use is not precluded, but should be discussed as experimental.
  • “You do you, whatever you want to do ... With an N of 26 in the treatment group, maybe need a little bit more data.” (Dr. Chapma, 19:52)
• Final Note:
  • Light-hearted pun: "I think we've met our function here. Get it? Our function. We were talking about sexual function." (Dr. Chapma, 20:20)

Notable Quotes & Memorable Moments

On the Placebo Effect and Mixed Outcomes

• Casual Commentator (01:28):
  “A lot of the women that I've injected, some women come in and say, ‘oh, my God, it's the best thing that's ever happened.’ I have some women that come and be like, ‘didn't feel much of a difference. I don't know.’”

On PRP Use and Regulation

• Dr. Chapma (06:12):
  “These are mainly all done off label, but they seem to work in certain dental surgeries. ... The difficulty, because this is all autologous ... is that it has to be unified and standardized. And right now you just can't order from a company your little vials of PRP.”

On Anatomical Plausibility and the G-spot

• Dr. Chapma (10:40):
  “The anterior vaginal wall absolutely is considered an erogenous zone. So the idea of anything that can plump that area up ... bring natural healing to this with platelet rich plasma, that's the idea.”

On the Study’s Statistical Significance

• Dr. Chapma (15:50):
  “Quote: ‘Although these changes were not statistically significantly different compared to control, end quote.’ ... Statistical significance is just math, and it could be because this was only 26 patients.”

On the Ongoing Nature of the Controversy

• Dr. Chapma (19:52):
  “You do you, whatever you want to do. I'm just saying with an N of 26 in the treatment group, maybe need a little bit more data because the FSFI overall showed no statistical differences in their subgroups. But you know, it's interesting.”

Important Segment Timestamps

| Timestamp | Segment Description | |-----------|--------------------| | 01:09–03:59 | Introduction to G-spot and G-shot, skepticism, historical background (Dr. 90210) | | 04:00–06:12 | Platelet-rich plasma origins, historical evolution, and off-label use | | 09:48–11:18 | Anatomical discussion: anterior vaginal wall, erogenous zones, and clitoral anatomy | | 12:50–20:22 | RCT design, results, appraisal, and broader clinical/ethical considerations | | 15:50 | Discussion of (lack of) statistical significance in the new study results | | 19:52 | Final thoughts on the need for more robust data and responsible off-label use |

Summary Takeaway

Dr. Chapa’s episode provides an evidence-based, balanced, and slightly irreverent look at the reemergence of G-spot injections for sexual function, in particular the recent exploration of PRP as an “amplifier” for the controversial erogenous zone. The verdict: Interesting for “water cooler discussion,” but with no statistically significant clinical benefit demonstrated and ongoing concerns over standardization, regulation, and scientific rigor, the procedure remains in the experimental domain. Medical providers are urged to use caution, transparency, and up-to-date research before considering or advising these interventions.